Vascular endothelial growth factor (VEGF), its inhibitory splice variant, VEGF165b and Endocrine Gland derived VEGF (EG-VEGF) have a controversial role in pituitary gland. We aim to study VEGF, VEGF165b and EG-VEGF expression in pituitary adenomas. A significant correlation was found between growth hormone (GH) and VEGF secretion (P=0.024). For prolactinomas, VEGF and prolactin expression, had a P-value of 0.02 for Kendall coefficient and a P-value of 0.043 for the Spearman coefficient. VEGF-mRNA amplification was detected in both tumor cells and folliculostellate cells. VEGF165b was positive in 16.66% of pituitary adenomas. EG-VEGF was significantly correlated with prolactin (P=0.025) and luteinizing hormone (P=0.028). Our data strongly support VEGF, VEGF165b and EG-VEGF as important players of pituitary adenomas tumorigenesis. Particular hormonal milieu heterogeneity, special vascular network with an unusual reactivity to tumor growth correlated with variability of VEGF, VEGF165b and EG-VEGF secretion may stratify pituitary adenomas in several molecular groups with a direct impact on therapy and prognosis.

中文翻译：

---

VEGF，VEGF165b和EG-VEGF的表达与垂体腺瘤中的激素谱特别相关。

血管内皮生长因子（VEGF），其抑制性剪接变体，VEGF165b和内分泌腺衍生的VEGF（EG-VEGF）在垂体中具有争议的作用。我们旨在研究垂体腺瘤中的VEGF，VEGF165b和EG-VEGF表达。发现生长激素（GH）与VEGF分泌之间存在显着相关性（P = 0.024）。对于泌乳素瘤，VEGF和催乳素的表达，Kendall系数的P值为0.02，Spearman系数的P值为0.043。在肿瘤细胞和卵泡细胞中均检测到VEGF-mRNA扩增。在16.66％的垂体腺瘤中VEGF165b是阳性的。EG-VEGF与催乳素（P = 0.025）和促黄体生成素（P = 0.028）显着相关。我们的数据强烈支持VEGF，VEGF165b和EG-VEGF作为垂体腺瘤肿瘤发生的重要因素。